Skip to content

Webinar: Human iPSC added value to the drug discovery pipeline

Ncardia author image

By Mariana Argenziano, PhD

Human induced pluripotent stem cell (iPSC)-based disease models provide an advantageous platform for drug discovery. Several available models have contributed to advances in cardiac and neurological research. With the advance of iPSC differentiation techniques, more cell-relevant disease models are available to explore, including those for muscle diseases such as Duchenne’s Muscular Dystrophy.

Nevertheless, implementation of iPSC-derived models in drug discovery projects involves several critical considerations. For instance, lineage specification of iPSCs to cell types that closely recapitulate key disease features and cell manufacturing at a commercial scale. Another critical step is reproducibility and development of high-throughput assays that measure the disease biology.

During the webinar -  we will discuss the advantages, challenges, and solutions of implementing iPSC-technology into drug discovery and development for muscle disease modeling.

In this webinar, you will learn about:

  • Critical parameters and considerations for commercial scale iPSC manufacturing
  • Advantages of implementing iPSC-technology
  • Challenges and solutions of implementing iPSC-technology
Nov 11_ Nov Research Highlights@1x (1)

Fill out the form to watch the replay: